Clinical trials: Multicenter Study
Advanced/Metastatic Solid Malignancies
IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
The study is to evaluate preliminary anti-tumor activity (overall response rate, ORR) of IBI308 monotherapy in subjects with advanced/metastatic solid malignancies.
- Trial name
- NCT03568539
- Testing
- IBI308
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Alzheimer Disease
Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment
The purpose of this study is to determine the safety and efficacy of TRx0237 16 mg/day and 8 mg/day in the treatment of subjects with Alzheimer's Disease compared to placebo.
- Trial name
- NCT03446001
- Testing
- TRx0237 16 mg/day, Control, TRx0237 8 mg/day
- Where
- 103 sites in United States, Belgium and 6 more
- Volunteers
- 598 people
- Sponsor
- TauRx Therapeutics Ltd
Psoriasis
Etanercept (Enbrel®) in Psoriasis - Pediatrics
This study will evaluate the safety and efficacy of etanercept (Enbrel®) in children with Psoriasis.
- Trial name
- NCT00078819
- Testing
- Etanercept
- Volunteers
- 211 people
- Sponsor
- Amgen
Hemostasis, Surgical
The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery
The primary purpose of the study is to compare the effect of perioperative (the time period describing the duration of a participants surgical procedure) administration of PROCRIT to that of Standard of Care (SOC) on the…
- Trial name
- NCT00350519
- Testing
- Epoetin alfa, Standard of Care
- Volunteers
- 37 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Dry Eye Disease
A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye
The purpose of this study is to evaluate the efficacy and safety of SI-614 ophthalmic solution compared with placebo in patients with dry eye
- Trial name
- SIDE (NCT05411367)
- Testing
- SI-614
- Where
- 6 sites in United States
- Volunteers
- 232 people
- Sponsor
- Seikagaku Corporation
Healthy Volunteers, Moderate to Severe Alzheimer Patients
A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
This is a dual-centre, Phase I/IIa study, in healthy subjects and subjects with AD to investigate the safety, tolerability, cognitive, and behavioural effects of RPh201.
- Trial name
- NCT01513967
- Testing
- RPh201, botanical drug product
- Where
- 2 sites in Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Regenera Pharma Ltd
Rheumatoid Arthritis
Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks
The study's objective is to compare the efficacy of 3 dose levels of oral CP-690,550 monotherapy (5 mg, 15 mg, and 30 mg twice daily [BID]) versus placebo administered over 6 weeks for the treatment of the signs and symptoms of…
- Trial name
- NCT00147498
- Testing
- CP-690,550
- Where
- 60 sites in United States, Belgium and 7 more
- Volunteers
- 264 people
- Sponsor
- Pfizer
Ulcerative Colitis
Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis
To assess clinical response to MMX mesalamine/mesalazine between a low and high dose in children and adolescents aged 5-17 years with mild to moderate Ulcerative Colitis (UC) or who are in remission.
- Trial name
- PACE (NCT02093663)
- Testing
- MMX Mesalamine/Mesalazine (Low Dose), MMX Mesalamine/Mesalazine (High Dose)
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 107 people
- Sponsor
- Shire
Alzheimer's Disease
Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease
The investigators hypothesize that Nilotinib will be safe in individuals with mild to moderate AD. Specifically, investigators hypothesize that low daily oral doses of Nilotinib will lead to CSF penetration, CNS Abl inhibition…
- Trial name
- AD (NCT02947893)
- Testing
- Nilotinib Capsule(s) Once a Day by Mouth
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Georgetown University
Tuberculosis, Meningeal
Adjunctive Linezolid for the Treatment of Tuberculous Meningitis
This is a phase II randomized open-label trial of high versus standard dose rifampin (RIF) with or without linezolid (LZD) for the first 4 weeks of treatment for Tuberculosis Meningitis (TBM) at Masaka Regional Referral Hospital…
- Trial name
- ALTER (NCT04021121)
- Testing
- LZD, High dose RIF, Standard dose RIF
- Where
- Uganda
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either…
- Trial name
- TRANSFORM-3 (NCT02422186)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 69 sites in United States, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Janssen Research & Development, LLC
Psoriatic Arthritis
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
The purpose of this study was to provide up to 52 weeks of efficacy, safety and tolerability data to support registration of intravenous (i.v.) secukinumab (Initial dose of 6 mg/kg at Baseline (BSL) followed thereafter with 3…
- Trial name
- INVIGORATE 2 (NCT04209205)
- Testing
- AIN457 6 mg/kg i.v., AIN457 3 mg/kg
- Where
- 80 sites in United States, Brazil and 13 more
- Volunteers
- 381 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoid Tumors
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Study evaluating SOM230 in patients with metastatic carcinoid tumors
- Trial name
- NCT00088595
- Testing
- Pasireotide (SOM230)
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
This single arm observational study will assess the duration and safety of treatment with trastuzumab in routine clinical practice in participants with early or metastatic HER2-positive breast cancer.
- Trial name
- HERODOT (NCT01187381)
- Testing
- Trastuzumab
- Where
- Romania
- Volunteers
- 250 people
- Sponsor
- Hoffmann-La Roche
Bone Metastasis, Cancer Pain
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
The purpose of this study is to determine whether tanezumab is effective in the treatment of cancer pain due to bone metastasis in patients already taking background opioid therapy.
- Trial name
- NCT02609828
- Testing
- Tanezumab
- Where
- 89 sites in Argentina, Australia and 14 more
- Volunteers
- 156 people
- Sponsor
- Pfizer
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir (SOF)/velpatasvir (VEL; GS-5816) fixed-dose combination (FDC) for 12 weeks in participants with chronic…
- Trial name
- NCT02671500
- Testing
- SOF/VEL
- Where
- 38 sites in China, Malaysia and 3 more
- Volunteers
- 375 people
- Sponsor
- Gilead Sciences
Cancer
Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma
This is a single-arm, phase II trial of SOM230 in patients with documented recurrent or progressive intracranial meningioma who have failed conventional therapy and are not candidates for complete surgical resection of their…
- Trial name
- NCT00813592
- Testing
- SOM230B
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Utah
Femoral Fractures
A Multicenter Randomized Trial Comparing IM Nails and Plate Fixation in Distal Femur Fractures
This study looks at two (2) types of surgical treatments and hopes to answer the question, "which is the best way to surgically treat a distal femur fracture?" Both procedures being studied are standard of care (used routinely)…
- Trial name
- NCT00429663
- Testing
- reamed, interlocking intramedullary nail, locking periarticular plate
- Where
- 22 sites in United States
- Volunteers
- 160 people
- Sponsor
- Boston Medical Center
Non-small Cell Lung Cancer
NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
Phase 2a Open-Label, Multicenter Trial of Naptumomab Estafenatox (NAP), following Obinutuzumab Pretreatment, on Days -13 and -12. NAP will be administered on Days 1-4 of treatment cycles 1-6, followed by docetaxel on Day 5.
- Trial name
- NT-NAP-102-1 (NCT04880863)
- Testing
- NAP (Naptumomab estafenatox), Docetaxel, Obinutuzumab
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- NeoTX Therapeutics Ltd.
Post-Stroke Spasticity, Cerebrovascular Accident
Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity
This is a study to confirm the superior efficacy of a single treatment of GSK1358820 over placebo in patients with post-stroke upper limb spasticity of both the wrist and finger flexors using the Modified Ashworth Scale (MAS)…
- Trial name
- NCT00460564
- Testing
- GSK1358820
- Where
- 18 sites in Japan
- Volunteers
- 109 people
- Sponsor
- GlaxoSmithKline